A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

August 19, 2027

Study Completion Date

August 19, 2027

Conditions

Hodgkin LymphomaB-Cell LymphomaRelapsed B-cell NHL

Interventions

DRUG

Mosunetuzumab

Given by IV (vein)

DRUG

Polatuzumab vedotin

Given by IV (vein)

DRUG

Tafasitamab

Given by IV (vein)

DRUG

Lenalidomide

Given by PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER